81 related articles for article (PubMed ID: 18664987)
1. The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART.
Sendagire H; Easterbrook PJ; Nankya I; Arts E; Thomas D; Reynolds SJ
AIDS Rev; 2009; 11(2):59-70. PubMed ID: 19529746
[TBL] [Abstract][Full Text] [Related]
2. Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors.
Rudick JG; Laakso MM; Schloss AC; DeGrado WF
Org Biomol Chem; 2013 Nov; 11(41):7096-100. PubMed ID: 24065278
[TBL] [Abstract][Full Text] [Related]
3. Novel Antiretroviral Agents.
Cambou MC; Landovitz RJ
Curr HIV/AIDS Rep; 2020 Apr; 17(2):118-124. PubMed ID: 32052271
[TBL] [Abstract][Full Text] [Related]
4. A Per-Protocol Analysis Using Inverse-Probability-of-Censoring Weights in a Randomized Trial of Initial Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Children.
Yin DE; Cole SR; Ludema C; Brookhart MA; Golin CE; Miller WC; McKinney RE
Am J Epidemiol; 2023 Jun; 192(6):916-928. PubMed ID: 36896583
[TBL] [Abstract][Full Text] [Related]
5. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.
Yin DE; Ludema C; Cole SR; Golin CE; Miller WC; Warshaw MG; McKinney RE;
PLoS One; 2020; 15(11):e0242405. PubMed ID: 33226999
[TBL] [Abstract][Full Text] [Related]
6. Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor.
Wolstein O; Boyd M; Millington M; Impey H; Boyer J; Howe A; Delebecque F; Cornetta K; Rothe M; Baum C; Nicolson T; Koldej R; Zhang J; Keech N; Camba Colón J; Breton L; Bartlett J; An DS; Chen IS; Burke B; Symonds GP
Mol Ther Methods Clin Dev; 2014; 1():11. PubMed ID: 26015947
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Hoque MT; Kis O; De Rosa MF; Bendayan R
Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
[TBL] [Abstract][Full Text] [Related]
8. Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
Lee JH; Hachiya A; Shin SK; Lee J; Gatanaga H; Oka S; Kirby KA; Ong YT; Sarafianos SG; Folk WR; Yoo W; Hong SP; Kim SO
Clin Microbiol Infect; 2013 Jun; 19(6):E263-70. PubMed ID: 23480551
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral resistance in HIV-infected Saudi children failing first-line highly active antiretroviral therapy.
Al Hajjar SH; Frayha H; Althawadi S
Ann Saudi Med; 2012; 32(6):565-9. PubMed ID: 23396017
[TBL] [Abstract][Full Text] [Related]
10. Analytical and biological considerations in the measurement of cell-associated CCR5 and CXCR4 mRNA and protein.
Campbell DE; Lai JP; Tustin NB; Riedel E; Tustin R; Taylor J; Murray J; Douglas SD
Clin Vaccine Immunol; 2010 Jul; 17(7):1148-54. PubMed ID: 20463101
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir.
Andrews E; Glue P; Fang J; Crownover P; Tressler R; Damle B
Br J Clin Pharmacol; 2010 Jan; 69(1):51-7. PubMed ID: 20078612
[TBL] [Abstract][Full Text] [Related]
12. Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.
Neely M; Kovacs A
Ther Clin Risk Manag; 2009 Jun; 5(3):595-615. PubMed ID: 19707276
[TBL] [Abstract][Full Text] [Related]
13. The distribution of CTL epitopes in HIV-1 appears to be random, and similar to that of other proteomes.
Schmid BV; Keşmir C; de Boer RJ
BMC Evol Biol; 2009 Aug; 9():184. PubMed ID: 19653887
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.
Rosso R; Bernardini C; Bruzzone B; Secondo G; Icardi G; Viscoli C; Di Biagio A
Eur J Med Res; 2009 Mar; 14(3):136-8. PubMed ID: 19380285
[TBL] [Abstract][Full Text] [Related]
15. Review of HIV antiretroviral drug resistance.
Chen TK; Aldrovandi GM
Pediatr Infect Dis J; 2008 Aug; 27(8):749-52. PubMed ID: 18664987
[No Abstract] [Full Text] [Related]
16. Newer antiretroviral agents and how to use them.
Kim HH; Daar ES
Curr HIV/AIDS Rep; 2009 May; 6(2):55-62. PubMed ID: 19358775
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 antiretroviral drug therapy.
Arts EJ; Hazuda DJ
Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a007161. PubMed ID: 22474613
[TBL] [Abstract][Full Text] [Related]
18. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
Zheng PR; Xue H; Xiao ZY; Liu G
Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
